AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26407893 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaire assessing self-sufficiency
Number of subjects: 581
Study 26407893 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Sufficiency Matrix for professionals (SSM-D)
Number of subjects: 581
Study 26407893 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report questionnaire and SSM-D combined
Number of subjects: 581
Study 23558545 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-free reinforcement-learning strategy
Number of subjects: 0
Study 23558545 — intervention group
Group type: COMPARATOR
Intervention: Model-based reinforcement-learning system
Number of subjects: 0
Study 21667366 — intervention group
Group type: EXPERIMENTAL
Intervention: Threat plus genetic prime message
Number of subjects: 125
Study 21667366 — intervention group
Group type: COMPARATOR
Intervention: Standard threat message
Number of subjects: 125
Study 21667366 — intervention group
Group type: COMPARATOR
Intervention: Self-identified racial/ethnic minority groups
Number of subjects: 125
Study 21667366 — intervention group
Group type: COMPARATOR
Intervention: Self-identified Caucasian smokers
Number of subjects: 125
Study 19524895 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic oophorectomy, ovarian tissue cryopreservation, and in vitro maturation of primary oocytes
Number of subjects: 1
Study 17023203 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g ascorbic acid daily for 4 weeks
Number of subjects: 39
Study 17023203 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 15010185 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy density (HED) foods
Number of subjects: 20
Study 15010185 — intervention group
Group type: COMPARATOR
Intervention: Low energy density (LED) foods
Number of subjects: 20
Study 15010185 — intervention group
Group type: EXPERIMENTAL
Intervention: Food unit size (small food unit (SFU) or customary food unit (CFU))
Number of subjects: 20
Study 15010185 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (HED and LED with SFU and CFU)
Number of subjects: 20
Study 11236112 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (n = 363; intravenous (iv) bolus dose of 6.75 mg, then 300 microg/minute iv for 3h and 100 microg/min iv thereafter)
Number of subjects: 742
Study 11236112 — intervention group
Group type: COMPARATOR
Intervention: Beta-agonists (n = 379; ritodrine, salbutamol or terbutaline iv; dose titrated)
Number of subjects: 742
Study 9661687 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 inhibitor concentrate
Number of subjects: 36
Study 9661687 — intervention group
Group type: COMPARATOR
Intervention: Placebo (albumin)
Number of subjects: 36
Study 7917371 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical mastectomy and radiotherapy
Number of subjects: 0
Study 7917371 — intervention group
Group type: COMPARATOR
Intervention: Mastectomy only
Number of subjects: 0
Study 2511744 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide treatment
Number of subjects: 81
Study 2511744 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 81
Study 4948416 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline, 2 doses daily for 3 days
Number of subjects: 0
Study 4948416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (multivitamins)
Number of subjects: 0
Study 29520816 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-assembling peptide matrix (SAPM) gel, applied ex-office over 1 week
Number of subjects: 50
Study 29520816 — intervention group
Group type: COMPARATOR
Intervention: 8% arginine and calcium carbonate (ACC) toothpaste, applied ex-office over 90 days
Number of subjects: 50
Study 26258927 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth service delivery model with combined pharmacotherapy and behavior training
Number of subjects: 223
Study 26258927 — intervention group
Group type: COMPARATOR
Intervention: Management in primary care augmented with a telepsychiatry consultation
Number of subjects: 223
Study 26258927 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatrists' decision making regarding medication adjustments
Number of subjects: 223
Study 26258927 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatrists' fidelity to chosen algorithms in medication management
Number of subjects: 223
Study 24898318 — intervention group
Group type: EXPERIMENTAL
Intervention: Equine facilitated learning (EFL) program, 11 weeks, once-weekly 90-min sessions
Number of subjects: 131
Study 24898318 — intervention group
Group type: COMPARATOR
Intervention: Waitlisted control group
Number of subjects: 131
Study 22907186 — intervention group
Group type: EXPERIMENTAL
Intervention: Microfat grafts with adipose-derived stem cells (ASCs)
Number of subjects: 10
Study 22907186 — intervention group
Group type: COMPARATOR
Intervention: Microfat grafts alone
Number of subjects: 10
Study 20616418 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy (TT) comprising clarithromycin, amoxicillin, omeprazole [n=23]
Number of subjects: 88
Study 20616418 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g Nigella sativa + 40 mg omeprazole [n=21]
Number of subjects: 88
Study 20616418 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g Nigella sativa + omeprazole [n=21]
Number of subjects: 88
Study 20616418 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g Nigella sativa + omeprazole [n=23]
Number of subjects: 88
Study 18520829 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications (specific combinations include timolol + dorzolamide, timolol + dorzolamide + pilocarpine)
Number of subjects: 378
Study 18520829 — intervention group
Group type: COMPARATOR
Intervention: No glaucoma (control group)
Number of subjects: 378
Study 18520829 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications (timolol + dorzolamide)
Number of subjects: 378
Study 18520829 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications (timolol + dorzolamide + pilocarpine)
Number of subjects: 378
Study 18520829 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical antiglaucoma medications
Number of subjects: 378
Study 18520829 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 378
Study 15784718 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GH dose (0.033 mg/kg.d or 0.1 IU/kg.d)
Number of subjects: 30
Study 15784718 — intervention group
Group type: EXPERIMENTAL
Intervention: High GH dose (0.067 mg/kg.d or 0.2 IU/kg.d)
Number of subjects: 30
Study 15784718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 15784718 — intervention group
Group type: EXPERIMENTAL
Intervention: GH (both low and high doses)
Number of subjects: 30
Study 12964289 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water
Number of subjects: 35
Study 12964289 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 35
Study 9387137 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein restriction
Number of subjects: 23
Study 7955757 — intervention group
Group type: EXPERIMENTAL
Intervention: Antigranulocyte antibody imaging
Number of subjects: 37
Study 7955757 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-phase bone scans
Number of subjects: 37
Study 3671899 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg/8 h) for 3 days prior to ascent and continued for 15 days at altitude
Number of subjects: 12
Study 3671899 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2767500 — intervention group
Group type: EXPERIMENTAL
Intervention: Intragastric balloon
Number of subjects: 24
Study 2767500 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 24
Study 30015697 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP therapy (40% fraction of inspired oxygen, 8 cm H2O CPAP)
Number of subjects: 40
Study 30015697 — intervention group
Group type: COMPARATOR
Intervention: COT (classic oxygen therapy via facemask at 6 L/min)
Number of subjects: 40
Study 30015697 — intervention group
Group type: COMPARATOR
Intervention: COT
Number of subjects: 40
Study 28880902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% + Clonidine 150μg/ml
Number of subjects: 21
Study 28880902 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine 0.5% + Saline (Placebo)
Number of subjects: 21
Study 28880902 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine + Clonidine
Number of subjects: 21
Study 25084754 — intervention group
Group type: EXPERIMENTAL
Intervention: State-anxiety induction
Number of subjects: 122
Study 25084754 — intervention group
Group type: COMPARATOR
Intervention: No state-anxiety induction (Control)
Number of subjects: 122
Study 23239151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,500 mg + pazopanib 800 mg (Cohort 1)
Number of subjects: 164
Study 23239151 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib 1,500 mg (Cohort 1)
Number of subjects: 164
Study 23239151 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib 1,500 mg (Cohort 2)
Number of subjects: 164
Study 23239151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib 1,000 mg + pazopanib 400 mg (Cohort 2)
Number of subjects: 164
Study 23239151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg (Cohort 2)
Number of subjects: 164
Study 21605022 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus
Number of subjects: 51
Study 21605022 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 51
Study 19212164 — intervention group
Group type: EXPERIMENTAL
Intervention: TransWarmer Infant Transport Mattress
Number of subjects: 115
Study 19212164 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 115
Study 16706613 — intervention group
Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20) treatment for 48 weeks
Number of subjects: 627
Study 16706613 — intervention group
Group type: COMPARATOR
Intervention: Baseline susceptibility to enfuvirtide
Number of subjects: 627
Study 16706613 — intervention group
Group type: COMPARATOR
Intervention: Baseline coreceptor tropism and viral subtype
Number of subjects: 627
Study 15841624 — intervention group
Group type: EXPERIMENTAL
Intervention: Myobloc (5,000 U per palm)
Number of subjects: 20
Study 15841624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.0 mL vehicle)
Number of subjects: 20
Study 11605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 6) on day 1 every 4 weeks
Number of subjects: 0
Study 11605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 100 mg/m(2)/wk for 3 weeks + carboplatin (AUC 2) weekly for 3 weeks
Number of subjects: 0
Study 11605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 150 mg/m(2)/wk + carboplatin (AUC 2 per week) during the second 8-week cycle
Number of subjects: 0
Study 11605178 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance weekly paclitaxel after initial treatment
Number of subjects: 0
Study 9663369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Number of subjects: 73
Study 9663369 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg of cerivastatin sodium once daily after the evening meal for 12 weeks
Number of subjects: 73
Study 9663369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg of cerivastatin sodium
Number of subjects: 73
Study 9663369 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg and 0.15 mg of cerivastatin sodium combined
Number of subjects: 73
Study 7839953 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or 5 or 10 tuberculin units of Tween‐80 stabilised purified protein derivative (P.P.D.)
Number of subjects: 112
Study 7839953 — intervention group
Group type: COMPARATOR
Intervention: Control group (volunteers)
Number of subjects: 112
Study 3342919 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention campaign in treated departments
Number of subjects: 0
Study 3342919 — intervention group
Group type: COMPARATOR
Intervention: No actions in control departments
Number of subjects: 0
Study 31735328 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with everolimus-eluting stents
Number of subjects: 1905
Study 31735328 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1905
Study 31735328 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge RHR (continuous variable per 5 bpm)
Number of subjects: 1905
Study 30624150 — intervention group
Group type: EXPERIMENTAL
Intervention: CP@clinic intervention (community-based, paramedic-led program for one year)
Number of subjects: 30
Study 30624150 — intervention group
Group type: EXPERIMENTAL
Intervention: CP@clinic intervention
Number of subjects: 30
Study 30624150 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 30
Study 29390528 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline plus PDT (n=48)
Number of subjects: 95
Study 26232120 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone
Number of subjects: 32
Study 26232120 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone + β‐TCP
Number of subjects: 32
Study 26232120 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐TCP alone
Number of subjects: 32
Study 23808581 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged conservative care protocol
Number of subjects: 93
Study 23808581 — intervention group
Group type: EXPERIMENTAL
Intervention: Utility scores from 8 weeks
Number of subjects: 93
Study 21350425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantogam activ (1800 mg/d)
Number of subjects: 40
Study 21350425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 21350425 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantogam activ
Number of subjects: 40
Study 19691566 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIG
Number of subjects: 28
Study 19691566 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19691566 — intervention group
Group type: EXPERIMENTAL
Intervention: hIVIG and glucocorticoids
Number of subjects: 28
Study 19691566 — intervention group
Group type: COMPARATOR
Intervention: Placebo and glucocorticoids
Number of subjects: 28
Study 17024947 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 specimens coated with resin and light cured for 10 seconds
Number of subjects: 16
Study 17024947 — intervention group
Group type: COMPARATOR
Intervention: Group 2 specimens left uncoated
Number of subjects: 16
Study 17024947 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 16
Study 12764909 — intervention group
Group type: EXPERIMENTAL
Intervention: Yishou Tiaozhi Tablet (YSTZT) 4 tablets 3 times a day for 60 days
Number of subjects: 168
Study 12764909 — intervention group
Group type: COMPARATOR
Intervention: Zocor 1 tablet before sleep every evening for 60 days
Number of subjects: 168
Study 11421893 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (grass pollen-specific allergy vaccine with MPL adjuvant)
Number of subjects: 81
Study 11421893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tyrosine alone)
Number of subjects: 81
Study 9240319 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (1 mg/kg/day)
Number of subjects: 40
Study 9240319 — intervention group
Group type: COMPARATOR
Intervention: Control (no azathioprine)
Number of subjects: 40
Study 7506322 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (25-50 mg o.d.)
Number of subjects: 12
Study 7506322 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100-200 mg o.d.)
Number of subjects: 12
Study 7506322 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Metoprolol (acute treatment)
Number of subjects: 12
Study 7506322 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Carvedilol (acute treatment)
Number of subjects: 12
Study 3300250 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid dialysates (1.1% and 2.0%)
Number of subjects: 0
Study 3300250 — intervention group
Group type: COMPARATOR
Intervention: Glucose dialysates (2.5% and 4.25%)
Number of subjects: 0
Study 31733336 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily soak-and-seal (SS) baths for 15 to 20 minutes (wet method)
Number of subjects: 42
Study 31733336 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily soak-and-seal (SS) baths (wet method)
Number of subjects: 42
Study 30326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy (3 MHz, 0.132 W/cm2, 1.3 W) applied daily for 4 hours over 6 weeks
Number of subjects: 90
Study 30326947 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 90
Study 30326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy
Number of subjects: 90
Study 30326947 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound therapy (in pilot subset)
Number of subjects: 90
Study 30326947 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (in pilot subset)
Number of subjects: 90
Study 27517053 — intervention group
Group type: EXPERIMENTAL
Intervention: ArmeoSpring training for 45 minutes daily, 5 days per week for 3 weeks, in addition to conventional rehabilitation
Number of subjects: 48
Study 23872080 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff-supported group (n=69)
Number of subjects: 128
Study 23872080 — intervention group
Group type: COMPARATOR
Intervention: Self-guided group (n=59)
Number of subjects: 128
Study 22218156 — intervention group
Group type: COMPARATOR
Intervention: Strength training only (ST group) for 90 days
Number of subjects: 45
Study 22218156 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training with fish oil supplementation (ST90 group) for 90 days (2 g/d)
Number of subjects: 45
Study 22218156 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training with fish oil supplementation (ST150 group) for 150 days (2 g/d, supplemented 60 days before training)
Number of subjects: 45
Study 20932341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular BMP-7 (1 mg)
Number of subjects: 33
Study 20932341 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular BMP-7 (0.1 mg and 0.3 mg)
Number of subjects: 33
Study 20932341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 20932341 — intervention group
Group type: EXPERIMENTAL
Intervention: OARSI responder criteria (BMP-7 groups)
Number of subjects: 33
Study 20932341 — intervention group
Group type: COMPARATOR
Intervention: OARSI responder criteria (Placebo)
Number of subjects: 33
Study 17660078 — intervention group
Group type: EXPERIMENTAL
Intervention: Group II (n=13) trained on the FLS videotrainer model until a proficiency score of 512 was achieved.
Number of subjects: 32
Study 17660078 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III (n=13) trained under constrained conditions to the same proficiency goal.
Number of subjects: 32
Study 17660078 — intervention group
Group type: COMPARATOR
Intervention: Group I (n=6) received no training.
Number of subjects: 32
Study 17660078 — intervention group
Group type: EXPERIMENTAL
Intervention: Group III trained longer (329+/‐71 minutes) and performed more repetitions (81+/‐15) than group II (239+/‐69 minutes and 59+/‐14 repetitions).
Number of subjects: 32
Study 15663444 — intervention group
Group type: EXPERIMENTAL
Intervention: Flowable restorative system (Bond 1 + Flow‐It!)
Number of subjects: 40
Study 15663444 — intervention group
Group type: COMPARATOR
Intervention: Conventional filled resin sealant (Fluroshield)
Number of subjects: 40
Study 11859235 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative autotransfusion with acute normovolemic hemodilution
Number of subjects: 80
Study 11859235 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving autotransfusion alone
Number of subjects: 80
Study 10435217 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive multicomponent school and community intervention
Number of subjects: 0
Study 8592597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg DFO test
Number of subjects: 77
Study 8592597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg DFO test
Number of subjects: 77
Study 8592597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg DFO test for detecting aluminium toxicity
Number of subjects: 77
Study 8592597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg DFO test for detecting aluminium toxicity
Number of subjects: 77
Study 8592597 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/kg DFO test for detecting aluminium overload
Number of subjects: 77
Study 8592597 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg DFO test for detecting aluminium overload
Number of subjects: 77
Study 1978481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride
Number of subjects: 18
Study 1978481 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine
Number of subjects: 18
Study 336257 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz
Number of subjects: 36
Study 336257 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 36
Study 30611752 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg/kg of body-mass)
Number of subjects: 15
Study 30611752 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28132795 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Field Sobriety Test (SFST)
Number of subjects: 0
Study 28132795 — intervention group
Group type: EXPERIMENTAL
Intervention: Hack's Impairment Index (HII)
Number of subjects: 0
Study 28132795 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Elizabeth Alcohol Intoxication Scale (STE)
Number of subjects: 0
Study 28132795 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 0
Study 28132795 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary Intoxication Question (BIQ)
Number of subjects: 0
Study 26919081 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% hydrogen peroxide in-office bleaching
Number of subjects: 30
Study 26919081 — intervention group
Group type: COMPARATOR
Intervention: 20% hydrogen peroxide in-office bleaching
Number of subjects: 30
Study 24252360 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib, 400 mg orally twice daily until disease progression or drug intolerance
Number of subjects: 12
Study 22999717 — intervention group
Group type: EXPERIMENTAL
Intervention: E‐ZES+3‐month DAPT, n=1059
Number of subjects: 2117